Trial Profile
A prospective observational study for safety and efficacy of Fulvestrant 500mg in postmenopausal patients with ER positive advanced or recurrent breast cancer after prior endocrine treatment. (SBCCSG-29)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2012
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Nov 2012 New trial record